-
BMO Capital Reiterates Outperform Rating on Replimune Group (REPL)
-
BMO Capital Reiterates Outperform Rating on Replimune Group (REPL)
-
BMO Capital Reiterates Outperform Rating on Replimune Group (REPL)
-
Replimune Announces Pricing of Public Offering
-
Replimune Group (REPL) PT Raised to $40 at BMO Capital Ahead of RP1 Data
-
Replimune Group (REPL) PT Lowered to $30 at BMO Capital, but Analyst Remains Optimistic on Shares Ahead of Near Term Catalysts
-
Replimune Group (REPL) PT Lowered to $55 at BMO Capital, Following Earnings
-
Replimune Group (REPL) PT Raised to $57 at BMO Capital
-
Replimune to Participate at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference
-
Replimune to Participate at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference
-
Replimune (REPL) Prices 2.826M Share Common Offering at $23/Sh
-
Replimune Announces Pricing of Upsized Public Offering
-
Replimune Announces Pricing of Upsized Public Offering
-
Replimune (REPL) Announces Proposed Common Share Offering
-
Replimune Announces Proposed Public Offering
-
Replimune Announces Proposed Public Offering
-
Replimune (REPL) Prices 3.678M Share Common Offering at $13.61/Sh
-
Replimune Announces Pricing of Public Offering
-
Replimune Announces Pricing of Public Offering
-
Replimune (REPL) Announces 5M Share Proposed Public Offering of Common Stock
-
Replimune Announces Proposed Public Offering
-
Replimune Announces Proposed Public Offering
-
Replimune to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
-
Replimune to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
-
BMO Capital Starts Replimune Group (REPL) at Outperform
-
Replimune (REPL) IPO Opens 7% Higher

